Search Browse Earnings

CytomX Therapeutics, Inc.

Nasdaq:CTMX

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CytomX Therapeutics, Inc. — SlamSEC

Revenue

$101.2M

+90.4% YoY

FY 2024

Adj. EBITDA

-$4.8M

-4.7% margin

FY 2024

Net Income

-$569,000

-0.6% margin

FY 2024

EPS (Diluted)

—

Stock Price

$5.03

+7.5%

2026-03-09

52W Range

$0.40 – $6.35

P/E Ratio

—

Market Cap

$852.3M

Cash

$17.2M

FY 2024

Total Debt

$1.6M

FY 2015

Net Cash

$15.6M

FY 2015

Enterprise Value

$836.7M

Debt / EBITDA

3.3x

FY 2024

EV / EBITDA

-176.1x

Employees

—